Triall logo
WebsiteTrustPad LaunchpadProstarter Launchpad

Triall (TRL)

ICO
IDO

Triall’s mission is to accelerate the introduction of safe and affordable vaccines and therapeutics into society by streamlining clinical trials.

IMPORTANT: By investing in this business you agree to ourDisclaimer. All information including our rating, is provided merely for informational purposes. CryptoTotem does not provide investment advice.

Overview

Project industryHealth & Medicine
Product typeEcosystem
FoundedNetherlands
WhitepaperTriall White Paper Open

What is Triall

Triall is laying the groundwork for tomorrow’s digital playing field in clinical trials. We bring Web 3.0 to medical research by developing a digital ecosystem of blockchain-integrated software solutions. Our blockchain infrastructure makes medical data tamper-resistant. It also enables secure and efficient connections between the many isolated systems and parties involved in clinical research. Our mission is to accelerate the introduction of safe and affordable vaccines and therapeutics into society by streamlining clinical trials.

We bring Web 3.0 to medical research, by realizing a digital ecosystem for clinical trials.

What are the unique benefits of the Triall ecosystem?

  • System Integration & Interoperability
  • Blockchain-agnostic, decentralized identity and access management. Secure connections and exchanges between isolated clinical trial systems and their users.
  • Efficiency & Operational Excellence
  • Integrated clinical trial metrics. Automation and assertion of clinical trial workflows through AI and smart contracts.
  • Data integrity & Auditability
  • Blockchain-secured, tamper-resistant audit trails of clinical documents and data.
  • Availability & Ease of Use

Ecosystem utilities available from anywhere. On any device. Through a secured cloud-based environment.

Details

IDO (TrustPad Launchpad): Sep 28, 2021 - Sep 28, 2021
IDO (Prostarter Launchpad): Sep 28, 2021 - Sep 28, 2021
Token supply: 175,000,000 TRL
Total tokens for sale: 18,250,000 TRL
Hard cap: 2,993,750 USD

Legal

Blockchain Platform: Ethereum
Registration country: Netherlands
Registration year: 2018
Office address: Bisonspoor 3002 – C701 (Copenhagen Tower), 3605 LT Maarssen, The Netherlands

Token info

Ticker: TRL
Type: Utility-token
Token standard: ERC20
Token price in USD: 1 TRL = 0,2 USD
Accepted currencies: USDT
Funds allocation:
Liquidity, long-term operations & development - 8%
18% - Pre-sale
24% - Treasury
10% - Triall Community Fund
12,5% - Existing investors
8% - Advisors
10% - Founding team
9,5% - Growth, acquisition & marketing

Project team

Hadil Es-Sbai, MSc
Hadil Es-Sbai, MSc
President | CEO
Hadil Es-Sbai, MSc linkedin
Niels Klomp, MSc
Niels Klomp, MSc
CTO
Niels Klomp, MSc linkedin
Dr. Linda van de Burgwal
Dr. Linda van de Burgwal
CFO
Dr. Linda van de Burgwal linkedin
Rob Posthumus, LL.M.
Rob Posthumus, LL.M.
General Counsel
Rob Posthumus, LL.M. linkedin
Raymond van der Waal, MSc
Raymond van der Waal, MSc
Head of Marketing
Raymond van der Waal, MSc linkedin
Dr. Joost Flach
Dr. Joost Flach
Head of Clinical Affairs
Dr. Joost Flach linkedin
Mark van der Waal, MSc
Mark van der Waal, MSc
Head of Product
Mark van der Waal, MSc linkedin

Advisors

Sina Djali
Sina Djali
Head of Integrated Data Analytics Janssen Pharmaceuticals (J&J)
Sina Djali linkedin
Danielle Bradbury
Danielle Bradbury
VP Quality Assurance Galera Therapeutics
Danielle Bradbury linkedin
Prof. Niels Chavannes, MD, PhD
Prof. Niels Chavannes, MD, PhD
Head of Research, Public Health & Primary Care Leiden University Medical Center
Prof. Niels Chavannes, MD, PhD linkedin
Cari Jacobs Blom
Cari Jacobs Blom
Director Quality & Compliance CR2O
Cari Jacobs Blom linkedin
Prof. Sjaak Bloem, PhD
Prof. Sjaak Bloem, PhD
Associate Director Behavioral Science Janssen Pharmaceuticals (J&J)
Prof. Sjaak Bloem, PhD linkedin
Allan Bukuya
Allan Bukuya
COO TrialDocs International
Allan Bukuya linkedin
Nick van den Bulk
Nick van den Bulk
Head Clinical Operations CR2O
Nick van den Bulk linkedin
Prof. Eric Claassen, PhD
Prof. Eric Claassen, PhD
Sequential Biotech Entrepreneur & Angel Investor Multiple ventures
Prof. Eric Claassen, PhD linkedin

Social media

Triall web-siteTriall MediumTriallYouTubeTriall TelegramTriall LinkedInTriall X (Twitter)Triall Facebook

One Response

  • dSeptember 27, 2021 at 12:11 am

    i like this project nice that i have invet in this project

    Reply
  • Leave a Reply

    Your email address will not be published. Required fields are marked *

    Sponsored Crypto Projects

    Newly Published